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Abstract
Background: Mechanisms of inflammation and protein accumulation are crucial in inclusion body myositis (IBM).
Recent evidence demonstrated that intravenous immunoglobulin failed to suppress cell-stress mediators in IBM.
Here we studied the molecular changes in skeletal muscle biopsies from patients with IBM before and after
treatment with alemtuzumab.
Methods: Relevant inflammatory and degeneration-associated markers were assessed by quantitative-PCR and
immunohistochemistry in repeated muscle biopsy specimens from patients with IBM, which had been treated in a
previously published uncontrolled proof-of-concept trial with alemtuzumab.
Results: There were no significant changes of the mRNA expression levels of the pro-inflammatory chemokines
CXCL-9, CCL-4, and the cytokines IFN-γ, TGF-β, TNF-α, and IL-1β. Similarly, the degeneration-associated molecules
ubiquitin, APP and αB-crystallin did not substantially change. Although no overall beneficial treatment effect was
noted except for a 6-month stabilization, some patients experienced a transient improvement in muscle strength. In
such responders, a trend towards reduced expression of inflammatory markers was noted. In contrast, the expression
remained unchanged in the others who did not experience any change. The expression levels of IL-1β and MHC-I
correlated with the positive clinical effect. By immunohistochemistry, some inflammatory mediators like CD8,
CXCL-9, and MHC-I were downmodulated. However, no consistent changes were noted for ubiquitin,
nitrotyrosin and β-amyloid.
Conclusions: Alemtuzumab showed a trend towards downregulation of the expression of some inflammatory
molecules in skeletal muscle of IBM patients but has no effect on several crucial markers of cell stress and
degeneration. The data are helpful to explain the molecular treatment effects of future lymphocyte-targeted
immunotherapies in IBM.
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Background
Inclusion body myositis (IBM), the most common myop-
athy in patients over 50 years of age, leads to a progressive
muscle weakness and atrophy [1]. Histopathological
examination in IBM muscles reveals two major features:
inflammation and degeneration [2]. Cytotoxic lympho-
cytes surround and invade non-necrotic myofibers and
proinflammatory chemo- and cytokines, such as CCL-2,
CCL-3, CCL-4, CXCL-9, IL-1β, TNF-α and TGF-β are
overexpressed. On the other hand, degeneration is present
with vacuoles and accumulation of unwanted and mis-
folded proteins like β-amyloid, phosphorylated tau,
TDP43 and α-synuclein [3]. Both processes are relevant to
the pathogenesis in IBM and seem to be related to each
other [4].
Despite the clearly demonstrated inflammatory patho-
mechanisms, immunosuppressive treatments failed to
show a clear benefit in IBM, including methotrexate,
mycophenolate-mofetil and the TNF-α blocker etanercept
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[5–9]. In controlled studies with IVIG, a significant effect
could be recognized on dysphagia [10], but no improve-
ment in limb strength could be observed [11, 12]. In an
uncontrolled proof-of-concept study with alemtuzumab in
13 IBM patients, a reduction of their disease progression
for up to six months was observed [13]. Alemtuzumab is a
monoclonal antibody directed against CD52 and therefore
leads to a profound depletion of peripheral lymphocytes
[14].
In the present study, we have analyzed the molecular
changes in skeletal muscle biopsies from the IBM patients,
who participated in the previous trial with alemtuzumab.
Methods
Patients and muscle biopsies
We used muscle biopsy specimen from skeletal muscle
of the 13 IBM patients, who received alemtuzumab in a
previous trial [13]. All patients were treated with a single
infusion of alemtuzumab at a dose of 1.2 mg/kg over
4 days not exceeding a total dose of 120 mg. Muscle
biopsies were performed prior and 6 months after treat-
ment with alemtuzumab at the same site. In most cases,
the biceps was used as standard muscle. Occasionally
the quadriceps was chosen, e.g. when the biceps was
severely atrophic. IRB-approved consent for use of their
samples had been obtained.
Extraction of RNA and quantitative PCR
For extraction of total RNA from muscle biopsies, the
RNeasy kit (Qiagen, Valencia, CA, USA) was used,
following the supplier’s instructions. The tissue was ho-
mogenized in 350 μl lysis buffer, RNA was subsequently
eluted in 30 μl water and stored at -80 °C.
For cDNA synthesis, SuperScript II reverse transcriptase
(Invitrogen, Darmstadt, Germany) was used, according to
the supplier’s instructions. Originated cDNA was ampli-
fied with master mix for real-time PCR (Invitrogen) using
6-carboxy-fluorescein (FAM)-labelled probes and specific
primers (Applied Biosystems, Carlsbad, CA, USA):
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH,
s99999905_m1); APP (Hs00169098_m1), TGF-β1
(Hs00171257_m); IL-1β (Hs00174\097_m1); ubiquitin
(Hs00430290_m1); CXCL-9 (Hs00171065_m1); αB-
crystallin (Hs00157107_m1); NCAM (Hs00169851_m1);
CCL-4 (Hs00605740_g1); IFN-γ (Hs00174143_m1); TNF-α
(Hs00174128_m1). Reactions were performed in duplicates
on a SDS 7500 Sequence Detection System (Applied
Biosystems), following the standard cycle protocol and in-
structions given by the supplier. Target mRNA-expression
was quantified using the c(t) method in relation to ex-
pression of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA as housekeeping gene.
Staining of muscle tissue
For immunohistochemistry, 5 μm frozen sections of all
muscle biopsies were fixed in acetone at -20 °C for
10 min. Primary antibodies were diluted in 1 % BSA.
Incubation was performed at room temperature for one
hour. Following primary antibodies were used: β-
amyloid (mouse clone 6E10, Signet, Dedham, MA);
MHC class I (rat clone YTH 862.2 from Serotec, Oxford,
UK); APP (rabbit polyclonal from Serotec, Oxford, UK);
iNOS (rabbit polyclonal from Chemicon/Millipore,
Billerica, MA); NCAM (mouse clone Eric-1 from
Labvision/Neomarkers, Fremont, CA); αB-crystallin
(rabbit polyclonal from Serotec); IL-1β (rabbit polyclonal
from Abcam, Cambridge, USA); CXCL-9 (goat polyclonal
from R&D); P-neurofilament (mouse clone SMI-31 from
Covance, Princeton, NJ, USA).
Consecutive sections of all patients were double-labelled
for 1) CXCL-9 and MHC-I; 2) NCAM and αB-crystallin;
3) IL-1β and β-amyloid; 4) iNOS and SMI-31. Goat-
derived Alexa 594 or Alexa 488 were used as secondary
antibodies and diluted in 1 % BSA. After mounting in
Fluoromount G (Southern Biotech, Alabama, USA), digital
photography was performed on a Zeiss Axiophot
microscope (Zeiss, Göttingen, Germany). Pictures were
taken by a cooled CCD digital camera (Retiga 1300,
Qimaging, Burnaby, BC, Canada) and visualized with
ImageProPlus software (MediaCybernetics, Bethesda,
MD). For quantification, two independant raters were
scoring the signal intensity on a scale ranging from 0 to 3
and the mean was defined as semiquantitative IHC-Score.
Statistics
For statistical analysis (t-test, Pearson correlation), p <
0.05 was used as significant value and all significant out-
liers (Grubb’s test) were excluded prior to analysis
(Graph Pad Prism V5, San Diego, CA, USA).
Results
Partial downmodulation of mRNA levels of inflammatory
mediators after alemtuzumab
The expression levels of several disease-relevant markers
of IBM were determined by quantitative PCR (Fig. 1).
The mRNA expression of pro-inflammatory chemokines
CXCL-9, CCL-4, IL-1β, IFN-γ, and TNF-α were down-
modulated after treatment in several patients, but no
statistical significance was observed. The expression
level of degeneration-associated molecules ubiquitin
and APP remained also unchanged before and after
treatment.
Partial reduction of inflammatory markers based on
immunohistochemical staining after alemtuzumab
In line with the mRNA-expression results, immunohisto-
chemical analysis of relevant pro-inflammatory mediators
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showed reduced expression levels in several patients,
but no statistical significance was reached (Fig. 2).
More specifically, CXCL-9 and MHC-I were dimin-
ished in the majority of the patients; in contrast,
markers for degeneration and cell stress, including
β-amyloid and αB-crystallin, remained unchanged
after treatment.
Subtype analysis of patients who experienced a temporary
improvement of strength after treatment vs. those who did
not
Although the study was small and uncontrolled, some
patients experienced a clear but short-lasting improve-
ment of weakness in arms and legs [13]. This response
was, however, heterogeneous. Four patients experienced
Fig. 1 GAPDH-normalized mRNA expression of inflammatory and degenerative markers. The mRNA-expression was assessed by
quantitative (real-time) polymerase chain reaction relative to GAPDH in skeletal muscle from patients with inclusion body myositis
(IBM) before (pre) and after (post) treatment with alemtuzumab. Subgroups are differentially labeled as responders (red) and
non-responders (blue)
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a gain of strength at 6 months after treatment as
reflected by quantitative muscle testing, MRC scale and
subjective improvement; for the purpose of this study,
we considered those as “responders”, even if the re-
sponse is not defined on a statistical basis but only on
careful observations collected by the non-treating exam-
iners; in contrast, 9 patients had no clear subjective or
objective benefit, and we considered them as “non-re-
sponders” [13]. The molecular differences between these
two groups were examined and compared with each
Fig. 2 Immunohistochemistry of inflammatory and degenerative markers in skeletal muscle of IBM patients before and after treatment with
alemtuzumab. No significant changes were observed for CD8, MHC-I, the proinflammatory chemokine CXCL-9 and the cytokine IL-1β. Similarly,
the degeneration-associated molecules nitrotyrosine, β-amyloid, αB-crystallin and NCAM remained without major variation. Subgroups are
differentially labeled as responders (red) and non-responders (blue)
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other. The mRNA expression levels of CXCL-9, CCL-4
(p = 0.048), IFN-γ, TGF-β, TNF-α, and IL-1β
(p = 0.0403) were downmodulated in the “responders”
compared to “non-responders” (Fig. 3). By contrast,
the expression rate of the de- and regeneration/ cell-
stress markers APP, αB-crystallin and desmin dis-
played a similar expression in both groups (Fig. 3). By
immunohistochemical staining, CD8 (p = 0.013),
CXCL-9 (p = 0.0095) and MHC-I (p = 0.042) were
clearly diminished in the “responders” compared to
“non-responders” (Fig. 3); this was in contrast to the
protein expression of β-amyloid, NCAM, nitrotyrosine
and αB-crystallin which remained unchanged in both
groups after treatment (Fig. 3). Accumulation of β-amyloid
showed also no difference, regardless of the clinical
outcome.
Discussion
In this study we demonstrate that one series of infusions
with alemtuzumab can reduce the expression of pro-
inflammatory molecules in some IBM patients, especially
those with the most noticeable clinical benefit, suggest-
ing that inflammatory mechanisms in IBM are of clinical
importance. Although various immunosuppressants or
immunomodulators may transiently help some IBM pa-
tients, several short-term controlled trials have failed to
demonstrate a beneficial effect, leading to the notion
that in IBM, the long-term degenerative process exerts
Fig. 3 Change of expression of relevant markers measured with qPCR and immunohistochemistry. Mean fold reduction of qPCR assessment (a, b)
and mean reduction in signal intensity (c, d) before versus after treatment for pro-inflammatory (a, c) and degeneration-associated molecules (b,
d). Assessment of semiquantitative immunohistochemistry analysis was done by two masked observers of skeletal muscle biopsies stainings from
all patients and the mean value is depicted. The group was divided into responders (red) and non-responders (blue). For pro-inflammatory
molecules, one can assume a reduction in expression for responders (qPCR: p = 0.048 for CCL-4, p = 0.0403 for IL-1β; immunohistochemistry: p = 0.013
for CD8+, p = 0.0095 for CXCL-9, p = 0.042 for MHC-I), whereas non-responders show an increase of expression of proinflammatory molecules.
Only one patient, who responded well to therapy, revealed an increase in CXCL-9 expression. In both groups, the change of expression of
degeneration-associated molecules did not differ, regardless of the clinical improvement
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the most deleterious effect compared to autoimmune
and inflammatory changes [3]. Our results from the
alemtuzumab trial are illuminating because they show
suppression of key inflammatory mediators –some of
which are connected to enhancing degeneration– in
connection with some clinical benefit [13]. Although this
was an uncontrolled proof-of-concept study with a small
number of patients dictating careful interpretation of
data, the noted correlation between the reduction of
proinflammatory markers with short clinical benefit in
some of the patients, suggests that a potent immunosup-
pressive treatment, if sustained over longer time periods,
may not only alter the proinflammatory muscle micro-
environment but may also affect the degenerative
process and result in a clinical benefit. One reason for
not observing a sustained effect might have been the
observation that alemtuzumab did not suppress all the
degenerative and cell-stressor molecules. Nitric oxide in
particular, a mediator between inflammation and degen-
eration, was also unchanged.
Similar data we obtained in the repeated muscle speci-
mens in a short-term controlled study with intravenous
immunoglobulin and prednisolone, where we demon-
strated that inflammatory markers were downmodulated
after therapy but not the cell-stress molecules like αB-
crystallin and degenerative molecules like APP [15]. Fur-
ther, compared to the experience with alemtuzumab in
MS patients [16, 17], the lack of effect in IBM might be
also related to using only one set of infusions since the
protocol was designed as a proof-of-concept study rather
than a clinical trial. One set of infusions could lead to a
different treatment response, considering the repletion
kinetics of different lymphocyte subsets [18]. Recently it
was shown that regulatory T-cells are reduced in IBM,
suggesting a role in pathogenesis [19] especially since
they can inhibit the lytic activity of cytotoxic T cells in
vitro [20]. Because alemtuzumab is reprogramming the
immune system [21] and could change the proposed im-
balance between cytotoxic and regulatory T-cells, a re-
peated set of infusions–even more than what is
necessary in multiple sclerosis (MS)– may be needed to
achieve a sustained effect on specific repletion patterns
in order to affect the noxious degenerative molecules.
Another possible explanation for the ineffectiveness or
unsustained efficacy of alemtuzumab could be the lack
of effect on cytokine expression, especially in those pa-
tients who did not experience any clinical benefit. In this
case, the upregulation of proinflammatory cytokines may
be independent of peripheral T-lymphocytes. Recently,
the blocking effect of IL-1β was tested in IBM-patients
in a small pilot study of 4 patients, demonstrating no
efficacy [22]. Whether there are different subsets of pa-
tients with IBM, some of whom may respond differently
to an immunosuppressive treatment, cannot be answered
so far. In this study, we were not able to identify potential
molecular markers that could predict the response to
alemtuzumab. Finally, it is possible that the muscle tissue
may not be sensitive enough to capture changes of the
molecules studied in such a short period.
Conclusion
In conclusion, our data show that a lymphocyte-targeted
immunotherapy can change the pro-inflammatory milieu
in some patients with IBM and this may correspond to a
better clinical outcome. Most importantly, several cru-
cial markers of cell stress and degeneration remain un-
changed, providing an explanation for lack of sustained
clinical benefit. In the future, clinical trials examining
the molecular inflammatory and degenerative changes in
the muscle and correlating them with clinical outcomes
may shed light in understanding the pathogenesis of
IBM.
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